Herpes Simplex Virus Treatment: Market Research Report

March 2012 | 300 pages | ID: HB6544FF197EN
Global Industry Analysts, Inc

Abstracts

This report analyzes the worldwide markets for Herpes Simplex Virus Treatment in US$ Million.

The report provides separate comprehensive analytics for the US, Europe, and Rest of World.

Annual estimates and forecasts are provided for the period 2009 through 2017.

Also, a six-year historic analysis is provided for these markets.

The report profiles 38 companies including many key and niche players such as Agenus, Inc., AiCuris GmbH & Co.KG, Astellas Pharma, Inc., BioVex, Clinigen Group, Cytogenix, Inc., Genocea Biosciences, GlaxoSmithKline Plc, Lumavita AG, NanoBio Corporation, NanoViricides, Inc., Novartis International AG, Sanofi, Starpharma Holdings Limited, and Vical.

Market data and analytics are derived from primary and secondary research.

Company profiles are primarily based upon search engine sources in the public domain.

Contents

I.INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations
Disclaimers
Data Interpretation & Reporting Level
Quantitative Techniques & Analytics
Product Definitions and Scope of Study

II. EXECUTIVE SUMMARY

1.INDUSTRY OVERVIEW

A Prelude to Herpes Simplex Virus Infection
Prevalence
HSV Treatment
Patent Expiries Of Select Leading HSV Therapeutics
Leading HSV Drug (Valtrex) Sales Decline Due to Generic Competition

Table 1. Leading Drugs in the Global Herpes Simplex Therapeutics Market (2007-2010): Value Sales for Valtrex/Zelitrex, Zovirax in US$ Million (includes corresponding Graph/Chart)

Table 2. US Sales of Zovirax Products (2009 & 2010) in US$ Million

Table 3. European Sales of Aldara (2008-2010) in US$ Million (includes corresponding Graph/Chart)

HSV2 Pipeline Analysis

2.TREATMENT OF HERPES SIMPLEX VIRUS INFECTION

Antiviral Treatment
Major Drugs
Valtrex (Valacyclovir)

Table 4. Global Sales of Valtrex: 2002-2008 (includes corresponding Graph/Chart)

Zovirax (Acyclovir)

Table 5. Global Sales Of Zovirax: 2002-2007 (includes corresponding Graph/Chart)

Famvir (Famciclovir)
Foscarnet (Foscavir)
Abreva (Docosanol)
Cidofovir (Vistide)
Denavir/ Vectavir (Penciclovir)
Herpid
Orajel Medicated Cold Sore Brush
Viroxyn
Vaccination
Natural Treatment
Other Treatment

3.HSV VACCINES – AN INSIGHT

List of Select Pipeline Therapeutic Vaccines for the Treatment of HSV-2
Select Clinical Trials’ Activity in the Herpes Simplex Vaccines Space
GSK to Discontinue Development of Simplirix™
GSK Initiates Phase III clinical Studies of Herpes Zoster Vaccine
Vical Presents Results from HSV-2 Vaccine Program
BioVex Begins Phase I Clinical Trial for Immuno VEXHSV2
Acambis Begins Preclinical Testing of HSV Vaccine

4.HERPES SIMPLEX VIRUS INFECTION - THE DISEASE, CAUSES, SYMPTOMS, AND DIAGNOSIS

Introduction
Structure of Herpes Virus
Biological Properties of Herpes Viruses
Different Types of Human Herpes Viruses
Latency in Herpes Virus Family
Antibody Response
HSV-1 and HSV-2 Infections
Causes
The Different Types of Herpes Infections
Oral Herpes
Transmission
Symptoms
Orolabial HSV Infections
Recurrent Orolabial Herpetic Infection
Genital Infections
Primary Genital Infection
Recurrent Genital Infection
Recurrent Genital Infections in Males
Recurrent Genital Infections in Females
Prevention
Diagnosis
HSV CNS Infection
Herpes Gladiatorum in Adolescent Wrestlers
Acute Herpetic Infections
Acute Herpetic Gingivostomatitis
Acute Herpetic Pharyngotonsillitis
HSV Infection in Neonates
Disseminated HSV Disease
Other HSV Infections
Herpes Whitlow
Primary Eye HSV Infection
HSV Infections In Different Age Groups
HSV Infection in Pregnant Women
HSV in Immunocompromised Patients
Morbidity and Mortality
Seriousness of Herpes Simplex Infection
Preventive Measures
Diagnosis of HSV Infection
Virologic Tests
Tzanck Smear Test
Polymerase Chain Reaction Tests
Serologic Tests
Biokit HSV-2
HerpeSelect
Western Blot Test
Type-Specific Assays Test
Tests for Herpes Encephalitis
Imaging Tests
Brain Biopsy

PCR

5.PIPELINE ANALYSIS

VivaGel Vaginal Microbicide
VivaGel® Retains Anti-viral Activity Against HSV and HIV
Simplivir™
HerpeCide

NB-001

Helicase-Primase Inhibitors

6.PRODUCT LAUNCHES AND APPROVALS

Medivir Launches ‘Xerese’ Cream for Cold Sores in the US
Actavis Launches Valaciclovir in Switzerland
Matrix Labs Receives FDA Approval for Valacyclovir Hydrochloride Tablets
Ranbaxy Pharmaceuticals Launches Valacyclovir Hydrochloride into US Market
Sirion Therapeutics Secures US FDA Approval for ZirganTM 0.15%
Meridian Life Science Introduces Herpes Simplex Virus Antigens

7.RECENT INDUSTRY ACTIVITY

Amgen Acquires BioVex
Antigenics Changes Name to Agenus
Clinigen Signs Agreement with AstraZeneca for Purchase of Foscavir
NanoViricides Inks R&D Deal with Dr. Ken S. Rosenthal’s Laboratory
New American Therapeutics Purchases US Rights of Denavir
GlaxoSmithKline Acquires Xeclear Marketing Rights from Medivir
Bausch & Lomb Acquires Zirgan® Marketing Rights for the US Market
Genocea In-Licenses HSV Patent Estate from University of Washington
Medivir Teams Up with Meda for Marketing Xerese in the US
GSK and NanoBio Ink Licensing Deal for NB-001
Mymetics Takes Over Bestewil Holding
Sanofi Pasteur Acquires Acambis
Profectus Enters into an Assignment and License Deal with Wyeth

8.FOCUS ON SELECT GLOBAL PLAYERS

Agenus, Inc. (US)
AiCuris GmbH & Co.KG (Germany)
Astellas Pharma, Inc. (Japan)
Clinigen Group (UK)
Cytogenix, Inc. (US)
Genocea Biosciences (US)
GlaxoSmithKline Plc. (UK)
Lumavita AG (Switzerland)
NanoBio Corporation (US)
NanoViricides, Inc. (US)
Novartis International AG (Switzerland)
Sanofi (France)
Starpharma Holdings Limited (Australia)
Vical (US)

9.GLOBAL MARKET PERSPECTIVE

Table 6. World Recent Past, Current & Future Analysis for Herpes Simplex Virus Treatment Market by Geographic Region – US, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)

Table 7. World Historic Review for Herpes Simplex Virus Treatment Market by Geographic Region – US, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

Table 8. World 15-Year Perspective for Herpes Simplex Virus Treatment Market by Geographic Region – Percentage Breakdown of Dollar Sales for US, Europe, and Rest of World Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)

III. MARKET

1.THE UNITED STATES

A. Market Analysis
Herpes Simplex Infection Increases in the US
HSV Infections In Different Races
Valtrex Dominates US HSV Prescription Market

Table 9. Leading Drugs in US Herpes Therapeutics Market (2011): Percentage Breakdown of New Prescriptions for Valtrex, Acyclovir, Zovirax, Aldara, Denavir, and Famvir (includes corresponding Graph/Chart)

Product Launches
Clinical Trials
Strategic Corporate Developments
Key Players
B. Market Analytics

Table 10. The US Recent Past, Current & Future Analysis for Herpes Simplex Virus Treatment Market with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)

Table 11. The US Historic Review for Herpes Simplex Virus Treatment Market with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

2.EUROPE

Market Analytics

Table 12. European Recent Past, Current & Future Analysis for Herpes Simplex Virus Treatment Market by Geographic Region – France, Germany, Italy, UK, Spain, Russia & Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)

Table 13. European Historic Review for Herpes Simplex Virus Treatment Market by Geographic Region – France, Germany, Italy, UK, Spain, Russia & Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

Table 14. European 15-Year Perspective for Herpes Simplex Virus Treatment Market by Geographic Region - Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK, Spain, Russia & Rest of Europe Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)

2A.FRANCE

A. Market Analysis
Key Player
B. Market Analytics

Table 15. French Recent Past, Current & Future Analysis for Herpes Simplex Virus Treatment Market with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)

Table 16. French Historic Review for Herpes Simplex Virus Treatment Market with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

2B.GERMANY

A. Market Analysis
Key Player
B. Market Analytics

Table 17. German Recent Past, Current & Future Analysis for Herpes Simplex Virus Treatment Market with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)

Table 18. German Historic Review for Herpes Simplex Virus Treatment Market with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

2C.ITALY

Market Analytics

Table 19. Italian Recent Past, Current & Future Analysis for Herpes Simplex Virus Treatment Market with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)

Table 20. Italian Historic Review for Herpes Simplex Virus Treatment Market with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

2D.THE UNITED KINGDOM

A. Market Analysis
Clinical Trials
Strategic Corporate Developments
Key Players
B. Market Analytics

Table 21. The UK Recent Past, Current & Future Analysis for Herpes Simplex Virus Treatment Market with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)

Table 22. The UK Historic Review for Herpes Simplex Virus Treatment Market with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

2E.SPAIN

Market Analytics

Table 23. Spanish Recent Past, Current & Future Analysis for Herpes Simplex Virus Treatment Market with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)

Table 24. Spanish Historic Review for Herpes Simplex Virus Treatment Market with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

2F.RUSSIA

Market Analytics

Table 25. Russian Recent Past, Current & Future Analysis for Herpes Simplex Virus Treatment Market with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)

Table 26. Russian Historic Review for Herpes Simplex Virus Treatment Market with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

2G.REST OF EUROPE

A. Market Analysis
Product Launch
Strategic Corporate Development
Key Players
B. Market Analytics

Table 27. Rest of European Recent Past, Current & Future Analysis for Herpes Simplex Virus Treatment Market with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)

Table 28. Rest of European Historic Review for Herpes Simplex Virus Treatment Market with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

3.REST OF WORLD

A. Market Analysis
Clinical Trial
Key Players
B. Market Analytics

Table 29. Rest of World Recent Past, Current & Future Analysis for Herpes Simplex Virus Treatment Market with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)

Table 30. Rest of World Historic Review for Herpes Simplex Virus Treatment Market with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

IV. COMPETITIVE LANDSCAPE

Total Companies Profiled: 38 (including Divisions/Subsidiaries - 41)
Region/CountryPlayers
The United States
Canada
Japan
Europe
France
Germany
The United Kingdom
Rest of Europe
Asia-Pacific (Excluding Japan)
Latin America